Unichem Laboratories Ltd
Unichem Laboratories Ltd is involved in pharmaceuticals
in Generics, APIs and Contract Manufacturing (CMO) areas.[1]
- Market Cap ₹ 4,059 Cr.
- Current Price ₹ 576
- High / Low ₹ 631 / 395
- Stock P/E 1,555
- Book Value ₹ 326
- Dividend Yield 0.00 %
- ROCE -1.06 %
- ROE -1.55 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 8.31% over past five years.
- Company has a low return on equity of -3.81% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1,005 | 1,044 | 1,091 | 1,221 | 576 | 666 | 968 | 904 | 1,124 | 943 | 1,072 | 1,442 | 1,485 | |
819 | 863 | 989 | 1,078 | 813 | 798 | 1,019 | 994 | 1,028 | 986 | 1,165 | 1,391 | 1,402 | |
Operating Profit | 186 | 181 | 102 | 142 | -237 | -132 | -52 | -89 | 95 | -43 | -93 | 51 | 83 |
OPM % | 18% | 17% | 9% | 12% | -41% | -20% | -5% | -10% | 8% | -5% | -9% | 4% | 6% |
14 | 84 | 20 | 19 | 366 | 2,737 | 94 | 98 | 47 | 42 | -71 | -27 | -24 | |
Interest | 2 | 2 | 2 | 2 | 2 | 3 | 1 | 1 | 1 | 2 | 9 | 10 | 9 |
Depreciation | 35 | 43 | 38 | 35 | 39 | 45 | 62 | 71 | 76 | 83 | 106 | 105 | 104 |
Profit before tax | 162 | 220 | 82 | 124 | 87 | 2,556 | -20 | -64 | 66 | -87 | -279 | -92 | -55 |
Tax % | 20% | 20% | 21% | 19% | -19% | -0% | -144% | -12% | 18% | -36% | 7% | 0% | |
130 | 177 | 64 | 100 | 104 | 2,557 | 9 | -56 | 54 | -55 | -300 | -92 | -55 | |
EPS in Rs | 14.33 | 19.52 | 7.09 | 11.06 | 11.43 | 363.48 | 1.25 | -8.00 | 7.68 | -7.87 | -42.57 | -13.09 | -7.82 |
Dividend Payout % | 31% | 41% | 28% | 18% | 26% | 1% | 320% | -50% | 52% | -51% | -9% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 3% |
5 Years: | 8% |
3 Years: | 9% |
TTM: | 26% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 101% |
Stock Price CAGR | |
---|---|
10 Years: | 10% |
5 Years: | 27% |
3 Years: | 27% |
1 Year: | 38% |
Return on Equity | |
---|---|
10 Years: | 12% |
5 Years: | -2% |
3 Years: | -4% |
Last Year: | -2% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 18 | 18 | 18 | 18 | 18 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
Reserves | 795 | 888 | 929 | 1,009 | 1,113 | 2,748 | 2,718 | 2,633 | 2,683 | 2,658 | 2,370 | 2,281 |
6 | 1 | 0 | 8 | 1 | 0 | 0 | 17 | 1 | 132 | 108 | 70 | |
314 | 300 | 274 | 306 | 371 | 346 | 298 | 361 | 420 | 318 | 394 | 499 | |
Total Liabilities | 1,133 | 1,207 | 1,222 | 1,342 | 1,503 | 3,108 | 3,030 | 3,025 | 3,119 | 3,122 | 2,886 | 2,864 |
426 | 394 | 396 | 381 | 468 | 555 | 789 | 829 | 850 | 963 | 1,236 | 1,165 | |
CWIP | 129 | 86 | 119 | 233 | 247 | 236 | 90 | 331 | 568 | 494 | 148 | 122 |
Investments | 140 | 120 | 153 | 111 | 89 | 979 | 1,042 | 668 | 520 | 390 | 41 | 44 |
437 | 607 | 555 | 617 | 698 | 1,338 | 1,109 | 1,197 | 1,181 | 1,275 | 1,462 | 1,532 | |
Total Assets | 1,133 | 1,207 | 1,222 | 1,342 | 1,503 | 3,108 | 3,030 | 3,025 | 3,119 | 3,122 | 2,886 | 2,864 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
180 | 87 | 88 | 117 | 141 | -66 | -251 | -42 | -33 | -158 | -117 | -42 | |
-127 | 35 | -62 | -87 | -132 | 1,648 | -323 | -36 | -73 | 104 | 241 | 60 | |
-51 | -98 | -47 | -39 | -9 | -930 | -45 | -21 | -45 | 96 | -62 | -48 | |
Net Cash Flow | 3 | 24 | -21 | -9 | -0 | 653 | -619 | -98 | -150 | 42 | 62 | -30 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 77 | 74 | 69 | 79 | 188 | 127 | 125 | 130 | 117 | 147 | 161 | 141 |
Inventory Days | 127 | 183 | 159 | 162 | 371 | 216 | 242 | 301 | 326 | 438 | 335 | 264 |
Days Payable | 153 | 149 | 122 | 153 | 334 | 220 | 170 | 199 | 159 | 150 | 170 | 132 |
Cash Conversion Cycle | 51 | 108 | 106 | 88 | 225 | 123 | 197 | 233 | 284 | 436 | 325 | 274 |
Working Capital Days | 62 | 102 | 95 | 100 | 233 | 190 | 222 | 221 | 208 | 286 | 267 | 206 |
ROCE % | 20% | 19% | 9% | 13% | -8% | 132% | -0% | -2% | 2% | -3% | -6% | -1% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 23 Aug
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9 Aug - Results for the quarter ended June 30, 2024, published in the newspapers on August 9, 2024.
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 8 Aug
- Shareholder Meeting / Postal Ballot-Outcome of AGM 8 Aug
- Change In Key Managerial Personnel For Determining And Disclosure Of Material Events 8 Aug
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Jun 2017TranscriptNotesPPT
-
Feb 2017Transcript PPT
-
Nov 2016Transcript PPT
-
Aug 2016Transcript PPT
-
Jun 2016Transcript PPT
-
Feb 2016Transcript PPT
Therapeutic Areas
The company manufactures and markets APIs and pharmaceutical formulations as branded & non-branded generics. The company’s products cater to diverse therapeutic areas such as cardiology, gas, diabetology, gastroenterology psychiatry, neurology, antibacterial, anti-infective, and pain management. [1]